Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study

Mark C. Genovese, Jeffrey Kaine, Mitchell B. Lowenstein et al.|Arthritis & Rheumatism|2008

Cited by 206